Literature DB >> 4080510

Determination of sulfinpyrazone and four metabolites in plasma and urine by high pressure liquid chromatography.

E G Lentjes, Y Tan, C A Van Ginneken.   

Abstract

An HPLC method for the simultaneous determination of sulfinpyrazone and its p-hydroxy, sulfone, sulfide and p-hydroxysulfide metabolites in human plasma and urine samples was developed. Optimization with regard to sample preparation and chromatographic conditions was investigated. In the final procedure samples were acidified with HCl, extracted with a 1 + 1 (vol/vol) mixture of 1-chlorobutane and chloroform; urine extracts were re-extracted with citrate buffer (pH 4.5). HPLC was performed on reversed phase (RP 8) columns with a 48 + 52 (vol/vol) mixture of ethanol and citrate buffer (pH 2.5) as the mobile phase. The lower limit of detection for sulfinpyrazone and the sulfide metabolite is 10 ng/ml, for the other metabolites it is 50 ng/ml. An example of application of this procedure to pharmacokinetic studies in a volunteer receiving a single oral dose of sulfinpyrazone is given.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4080510     DOI: 10.1007/BF01959198

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  39 in total

1.  The Anturane Reinfarction Trial: reevaluation of outcome.

Authors: 
Journal:  N Engl J Med       Date:  1982-04-22       Impact factor: 91.245

2.  FDA says no to anturane.

Authors:  G B Kolata
Journal:  Science       Date:  1980-06-06       Impact factor: 47.728

3.  Two metabolites of sulphinpyrazone and their identification and determination by mass spectrometry.

Authors:  P Jakobsen; A K Pedersen
Journal:  J Pharm Pharmacol       Date:  1981-02       Impact factor: 3.765

4.  Biotransformation and pharmacokinetics of sulfinpyrazone (Anturan) in man.

Authors:  W Dieterle; J W Faigle; H Mory; W J Richter; W Theobald
Journal:  Eur J Clin Pharmacol       Date:  1975-12-19       Impact factor: 2.953

5.  Sulphinpyrazone metabolism during long-term therapy.

Authors:  A K Pedersen; P Jakobsen
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

Review 6.  Mechanisms of action of sulphinpyrazone.

Authors:  R B Wallis
Journal:  Thromb Res Suppl       Date:  1983

7.  Paired-ion high-performance liquid chromatographic assay for sulfinpyrazone in plasma.

Authors:  N J Patel; D O Kildsig; G S Banker; P R Mayer; M A Gonzalez
Journal:  J Pharm Sci       Date:  1982-12       Impact factor: 3.534

8.  The effects of two different dosage regimens of sulphinpyrazone on platelet function ex vivo and blood chemistry in man.

Authors:  E D Maguire; G F Pay; J Turney; R B Wallis; M J Weston; A M White; L C Williams; H F Woods
Journal:  Haemostasis       Date:  1981

9.  The effect of sulphinpyrazone and its metabolites on platelet function in vitro and ex vivo.

Authors:  G F Pay; R B Wallis; D Zelaschi
Journal:  Haemostasis       Date:  1981

10.  Plasma levels and effects of sulfinpyrazone in patients requiring chronic hemodialysis.

Authors:  M M Bern; B M Cavaliere; G Lukas
Journal:  J Clin Pharmacol       Date:  1980 Feb-Mar       Impact factor: 3.126

View more
  1 in total

1.  Renal clearance of sulphinpyrazone in man.

Authors:  E G Lentjes; F G Russel; C A van Ginneken
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.